PanGeo Pharma Inc., of Montreal, appointed Daniel Pharand executive vice president, business development.
Parexel International Corp., of Boston, appointed Susan Warren vice president, corporate marketing and strategy.
Phylos Inc., of Lexington, Mass., appointed Michael Furlong senior director, business development.
Praxis Pharmaceuticals Inc., of Canberra, Australia, added Austin Brewin as North American medical director.
Prolinx Inc., of Bothell, Wash., added Charles Campbell to its scientific advisory board.
Psychiatric Genomics Inc., of Gaithersburg, Md., named David Theil chief financial officer.
PTC Therapeutics Inc., of South Plainfield, N.J., appointed John Babiak senior vice president of drug discovery technologies.
Pyrosequencing AB, of Uppsala, Sweden, appointed Mats Bergstrvm European sales director.
Renovis Inc., of South San Francisco, added Edward Scolnick to its board.
Samaritan Pharmaceuticals Inc., of Las Vegas, added Jean-Paul Tillement to its scientific advisory board.
Scios Inc., of Sunnyvale, Calif., appointed Jane Moffitt vice president, regulatory affairs, and promoted Michael Crockett to director, project management.
Select Therapeutics Inc., of Woburn, Mass., named Douglas McNair senior vice president of clinical and regulatory affairs.
StemCells Inc., of Palo Alto, Calif., added Ricardo Levy to its board.
Structural GenomiX Inc., of San Diego, appointed Kevin D¿Amico vice president of synchroton radiation research.
SuperGen Inc., of Dublin, Calif., named Edward Jacobs chief business officer and chief financial officer.
Synsorb Biotech Inc., of Calgary, Alberta, added Beat Ernst, Gerald Hart and Stephen Hanessian to its scientific advisory board.
Targeted Genetics Corp., of Seattle, appointed Todd Simpson vice president, finance and administration, and chief financial officer.
The Institute for Genomic Research, of Rockville, Md., added Barbara Culliton as vice president for publishing and editor in chief of the Genome News Network.
Third Wave Technologies Inc., of Madison, Wis., appointed John Puisis chief financial officer.
Transkaryotic Therapies Inc., of Cambridge, Mass., appointed Mary Consalvi vice president and chief intellectual property counsel.
ViaCell Inc., of Boston, added Jan Visser as vice president of stem cell research.
Viaken Systems Inc., of Gaithersburg, Md., appointed Michael Sullivan chief financial officer.
Vical Inc., of San Diego, appointed David Kaslow chief scientific officer and Kevin Bracken vice president, manufacturing.
Xcyte Therapies Inc., of Seattle, appointed Mark Frohlich medical director.
YM BioSciences Inc., of Mississauga, Ontario, appointed Julius Vida to its board.